Top Markets
#1 DogBull DogBull +54.88%
#2 Siren Siren +31.44%
#3 OriginTrail OriginTrail +17.48%
#4 Yield Basis Yield Basis +10.34%
#5 龙虾 (Lobster) 龙虾 (Lobster) +8.85%
#6 MetYa MetYa +8.10%
#7 LayerZero LayerZero +7.76%
#8 COTI COTI +7.55%
#9 Stargate Finance Stargate Finance +7.55%
#10 Cysic Cysic +7.12%
Coin of the day
DogBull DogBull
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
3D Medicines Inc. 3D Medicines Inc.

3D Medicines Inc.

1244
Peringkat dalam Saham #22092
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a... Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
Harga Saham
$0.38441832
Terakhir disinkronkan: 2026-08-21
Kapitalisasi Pasar
$94.54M
Perubahan (1 hari)
-12.13%
Perubahan (1 tahun)
-62.78%
Negara
CN
Perdagangan 3D Medicines Inc. (1244)

Kategori

Healthcare
Rasio P/E untuk 3D Medicines Inc. (1244)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari 3D Medicines Inc., rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk 3D Medicines Inc. dari 2026 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.